InvestorsHub Logo
Post# of 251715
Next 10
Followers 97
Posts 92809
Boards Moderated 4
Alias Born 10/29/2007

Re: None

Monday, 03/31/2014 9:00:07 AM

Monday, March 31, 2014 9:00:07 AM

Post# of 251715
Glaxo pulls plug on expanded use of Votrient
After additional analysis of Phase 3 trial data, GlaxoSmithKline (GSK) decides to withdraw its European application for the use of Votrient (pazopanib) in advanced ovarian cancer.
Although initial results showed an improvement in progression-free survival, further analysis failed to show a sufficient benefit-to-risk ratio to proceed.
http://www.reuters.com/article/2014/03/31/us-glaxosmithkline-brief-idUSBREA2U0PB20140331

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.